ImmuCell Corp
ICCC
查看详细走势图
5.970USD
-0.170-2.77%
收盘 12/19, 16:00（美东）报价延迟15分钟
54.00M总市值
21.77市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.77%
5天
-3.86%
1月
+29.78%
6月
-21.45%
今年开始到现在
+15.92%
1年
+35.37%
查看详细走势图
TradingKey ImmuCell Corp股票评分
单位: USD 更新时间: 2025-12-19操作建议
ImmuCell Corp当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名110/158位。机构持股占比非常高，中期看，股价处于平稳状态。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
ImmuCell Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ImmuCell Corp亮点
亮点风险
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
业绩高增长
公司营业收入稳步增长，连续3年增长42.68%
业绩增长期
公司处于发展阶段，最新年度总收入26.49M美元
估值高估
公司最新PE估值21.77，处于3年历史高位
机构减仓
最新机构持股1.81M股，环比减少4.46%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值157.29K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.54
ImmuCell Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ImmuCell Corp简介
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
公司代码ICCC
公司ImmuCell Corp
CEOte Boekhorst (Olivier)
网址https://immucell.com/
常见问题
ImmuCell Corp(ICCC)的当前股价是多少？
ImmuCell Corp(ICCC)的当前股价是 5.970。
ImmuCell Corp的股票代码是什么？
ImmuCell Corp的股票代码是ICCC。
ImmuCell Corp股票的52周最高点是多少？
ImmuCell Corp股票的52周最高点是7.600。
ImmuCell Corp股票的52周最低点是多少？
ImmuCell Corp股票的52周最低点是4.280。
ImmuCell Corp的市值是多少？
ImmuCell Corp的市值是54.00M。
ImmuCell Corp的净利润是多少？
ImmuCell Corp的净利润为-2.16M。
现在ImmuCell Corp(ICCC)的股票是买入、持有还是卖出？
根据分析师评级，ImmuCell Corp(ICCC)的总体评级为--，目标价格为--。
ImmuCell Corp(ICCC)股票的每股收益（EPS TTM）是多少
ImmuCell Corp(ICCC)股票的每股收益（EPS TTM）是0.274。
相关品种
